Jaguar Health Secures New Patent for Crofelemer in Hong Kong

Jaguar Health, Inc. announced that Hong Kong's Intellectual Property Department has granted a new patent for methods treating short bowel syndrome (SBS) using crofelemer, Jaguar's plant-based prescription drug. This marks a significant enhancement in the company's intellectual property protection for its core rare disease target indication.

The issued patent covers treatment for SBS, bile acid diarrhea, and diarrhea associated with small intestine resection or gallbladder removal. Jaguar Health's CEO Lisa Conte expressed satisfaction with the patent issuance, noting it strengthens their IP portfolio.

Currently, Jaguar supports independent investigator-initiated studies of crofelemer for SBS and microvillus inclusion disease (MVID) in the US, Europe, and MENA regions. Results are anticipated by the end of 2024 and throughout 2025. This ongoing research could expedite patient access to crofelemer in various EU countries.

Jaguar and its subsidiary Napo Pharmaceuticals have a robust IP portfolio with approximately 230 patents issued or pending. Crofelemer remains the only oral, plant-based prescription drug approved under the FDA's Botanical Guidance, providing an exclusivity advantage due to its unique production requirements.